← SynDRA
NILUTAMIDE
SynDRA canonical compound SYN0004991 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | AR |
|---|
| Mechanism of action | Androgen receptor antagonist |
|---|
| Indication | prostate cancer |
|---|
| Disease area | oncology |
|---|
All known targets
Mechanisms of action (all sources)
Drug classes
- Androgen Receptor Antagonists
- Androgen Receptor Inhibitor
- Androgen Antagonists
- Antineoplastic Agents
- Hormone Antagonists
ATC classes
- L02B · HORMONE ANTAGONISTS AND RELATED AGENTS
Cross-references
Synonyms
- nilandrone
- anandron
- nilandron
- Nilutamida
- NSC-758683
- RU-23908
- Anadron
- Nilandron
- Anandron
- Nilandrone
- Nilutamidum
- Aventis Behring Brand of Nilutamide
- Aventis Brand of Nilutamide
- Hoechst Brand of Nilutamide
- Nilutamida [Spanish]
- Nilutamidum [Latin]
- N 8534
- Anandron (TN)
- RU 23908-10
- Nilutamide (USAN/INN)
- Nilutamide [USAN:BAN:INN]
- Nilutamide [USAN:INN:BAN]
- 1-(3'-Trifluoromethyl-4'-nitrophenyl)-4,4-dimethylimidazolidine-2,5-dione
- 5,5-Dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)-2,4-imidazolidinedione
- 5,5-Dimethyl-3-(alpha,alpha,alpha-trifluoro-4-nitro-m-tolyl)hydantoin
- 5,5-Dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-2,4-imidazolidinedione
- 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione
- 5,5-dimethyl-3-(4-nitro-3-(trifluoromethyl)phenyl)imidazolidine-2,4-dione
- RU 23908
- Nilandron;RU 23908
- NSC 758683
- CHEMBL1274
- CHEBI:7573
- 2,4-Imidazolidinedione,5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-
- 2,4-IMIDAZOLIDINEDIONE, 5,5-DIMETHYL-3-(4-NITRO-3-(TRIFLUOROMETHYL)PHENYL)-
- 51G6I8B902
- NCGC00015754-08
- CAS-63612-50-0
Reported adverse events
- Interstitial pneumonitis
- Abdominal pain
- Alcohol intolerance
- Arthritis
- Asthenia
- Back pain
- Cataract
- Chest pain
- Chromatopsia
- Constipation
- Cough
- Depression
Look up NILUTAMIDE in the interactive SynDRA portal →